|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Ten human cancer lines were investigated: colorectal carcinomas HCT116 and RKO [TP53 wild-type (WT)] and their respective TP53 null isogenic lines; breast adenocarcinomas MCF7 (TP53 WT) and MDA-MB-231 (TP53 Mut); lung carcinomas A549 (TP53 WT) and NCI-H1975 (TP53 Mut); and pancreatic carcinomas Hs766T (TP53 WT) and Panc-1 (TP53 Mut).
|
28813624 |
2017 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
The lung cancer subtypes share some genetic variations such as the dysfunction of tumor suppressor gene TP53, and also harbor specific variations of their own such as MET in ADC, FGFR1 and FGFR3 in SCC and MYC in SCLC.
|
27845189 |
2017 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Finally, in spite of all 16 tumors being HPV-16/18 positive, 3 of 8 squamous cell cancers and 2 of 5 adenocarcinomas expressed wild-type p53 protein.
|
28375929 |
2017 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Our systematic analysis of proteins and glycoproteins demonstrates changes of protein and glycoprotein relative abundance in SqCC (TP53, U2AF1, and RXR) and in ADC (SMARCA4, NOTCH1, PTEN, and MST1).
|
28814946 |
2017 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
We show that p53 loss before OIS is permissive for the transition from lung adenoma to adenocarcinoma.
|
28745322 |
2017 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
In addition, we detected the rare R213R (rs1800372, minor allele frequency: 0.0054) polymorphism in 7.2% of the patients and are the first to show the significant association with TP53 mutations in non-small cell lung cancer adenocarcinoma patients (p = 0.003).
|
28240049 |
2017 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In adenocarcinoma, High-MAGEA2 was strongly associated with aberrant p53 expression (P<0.001) and was associated with worse clinical outcomes (5-year OS, 87.1% in low vs. 74.1% in high, P=0.014).
|
28498455 |
2017 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
We evaluated the role of TP53/KRAS comutation in all patients and in the adenocarcinoma subgroup as well as the TP53/EGFR comutation in adenocarcinoma only through a multivariable Cox proportional hazards model stratified by trial.
|
28453411 |
2017 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Using a genetically engineered mouse lung cancer model, we show that Yap deletion completely blocks KrasG12D and p53 loss-driven adenocarcinoma initiation and progression, whereas heterozygosity for Yap partially suppresses lung cancer growth and progression.
|
29340023 |
2017 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Both tumor phenotypes resulted characterized by a p.E542K point mutation in the PIK3CA gene, whereas adenocarcinoma component revealed also a TP53 Q331* homozygous stop mutation.
|
28698100 |
2017 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
By contrast, mice with both alterations (Hoxb13-MYC∣Hoxb13-Cre∣Pten(Fl/Fl), hereafter, BMPC mice) developed lethal adenocarcinoma with distant metastases and widespread genome CNAs that were independent of forced disruption of Tp53 and telomere shortening.
|
26554830 |
2016 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Other notable GAs include TP53 in >45% of each histotype; NOTCH1: adenocarcinoma, NOS (7.7%), ca ex PA (8.3%), carcinoma, NOS (21.6%); NF1: adenocarcinoma, NOS (9.6%), SDC (17.1%), carcinoma, NOS (18.8%).
|
27334835 |
2016 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The results of the present study revealed that there is no association between P53 codon 72 polymorphism and increased risk of lung cancer in patients and controls but according to results of adenocarcinoma in never-smoker patients, it seems that environmental factors may have more important role than genetic susceptibility in our ethnic Iranian population.
|
27585259 |
2016 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Seven of 17 cases (41%) were reclassified in the adenocarcinoma with solid pattern group, which showed one KRAS G12C and one EGFR E709K + G719C double mutation in addition to mutations in TP53.
|
26430808 |
2016 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
IPA analyses showed adenocarcinoma-specific promoter DMxDE overlay identified familiar lung cancer nodes [tP53, Akt] as well as less familiar nodes [HBEGF, NQO1, GRK5, VWF, HPGD, CDH5, CTNNAL1, PTPN13, DACH1, SMAD6, LAMA3, AR].
|
26683690 |
2015 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The tumor suppressor TP53 is mutated in approximately 30% of breast adenocarcinomas, with varying frequency across molecular subtypes.
|
25351767 |
2015 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Formalin Fixed Paraffin Embedded tissue were studied for miRNA expression, KRAS, BRAF, PIK3CA mutations, and immuno-histochemistry for APC and p53 proteins for normal colon (n=11), hyperplastic polyps (n=11), high grade adenomas (n=10), low grade adenomas (n=34) and adenocarcinoma (n=13).
|
25496852 |
2015 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In non-small cell lung cancer (NSCLC), both USP7 expression and p53 gene status were reported to be an indicator of poor prognosis in adenocarcinoma patients; however, its roles and mechanisms in lung squamous cell carcinoma and large cell carcinoma need to be clarified.
|
25519684 |
2015 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
According to the analysis, typical EBV-associated gastric adenocarcinoma constitutes an independent molecular pathological subgroup, which is mutually exclusive to TP53-mutated adenocarcinoma with chromosomal instability, another molecular pathological subtype in gastric adenocarcinomas.
|
26617924 |
2015 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Twenty-four cases featuring TTF1+/p40-, TTF1+/p40±, TTF1-/p40±, or TTF1-/p40- phenotypes comprised ATM, BRAF, CDKN2A, EGFR, ERBB4, FBXW7, FLT3, KRAS, NRAS, PIK3CA, PTPN11, RET, SMAD4, SMO, STK11, or TP53 mutations in keeping with ADC lineage, whereas three tumors showing TTF1-/p40+ phenotype harbored TP53 only and no ADC-related mutations in keeping with SQC lineage.
|
26317919 |
2015 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Using genetically engineered mouse models, we show that heterozygous mutation of Dpc4/Smad4 attenuates the metastatic potential of Kras(G12D/+);Trp53(R172H/+) pancreatic ductal adenocarcinomas while increasing their proliferation.
|
26004068 |
2015 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Strong immunoreactivity of Bcl-2 and mild immunoreactivities of Bax and p53 were detected in ovarian adenocarcinomas.
|
25108507 |
2014 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
The authors show that combined loss of autophagy and p53 dramatically promotes progression from early Pancreatic Intraepithelial Neoplasia (PanIN) lesions towards adenocarcinoma and alters the cellular metabolism with an enrichment of anabolic pathway that can fuel the tumor growth.
|
24939064 |
2014 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Overexpression of p53 was detected only in high-grade dysplasia and invasive adenocarcinoma.
|
24603588 |
2014 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
We find very little evidence for dissemination from oncogenic KRAS-driven hyperplasias or most adenocarcinomas. p53 loss is insufficient to drive dissemination but rather enables rare cancer cells in a small fraction of primary adenocarcinomas to gain alterations that drive dissemination.
|
24740995 |
2014 |